Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Conditions
Interventions
efanesoctocog alfa (BIVV001)
Locations
4
United States
University of Iowa_Investigational Site Number :8400002
Iowa City, Iowa, United States
Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001
Pittsburgh, Pennsylvania, United States
Investigational Site Number :2500001
Lille, France
Investigational Site Number :2500002
Nantes, France
Start Date
May 3, 2021
Primary Completion Date
December 1, 2022
Completion Date
December 20, 2022
Last Updated
September 25, 2025
Lead Sponsor
Bioverativ, a Sanofi company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions